EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›GNLX

GNLX

GENELUX Corp

Next earnings Aug 3, 2026 · consensus $-0.20 EPS

Sell
$2.87
▼ -1.03%
$2.87▼ -4.01%
over 1Y
L $2.35EODHDH $8.11
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-1.0%
1W-1.0%
1M-6.2%
3M+15.7%
YTD-36.9%
1Y-4.0%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Sell
Quality
F
Valuation
Fair value
Filings
Watch
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 12 analysts
Buy

Conservative balance sheet (liabilities/equity 0.65x); but unprofitable (net margin -401812.5%).

Revenue (FY2025) $8.00K · FY2025

GENELUX Corp shows $8.00K in FY2025 revenue (+0.0% YoY), a -401812.5% net margin, and -278.5% ROE.

Financials · annual, by fiscal year

Line itemFY22FY23FY24FY25
Revenue$11.1M$170K$8.00K$8.00K
Gross profit————
Operating income-$3.01M-$24.2M-$31.7M-$33.2M
Net income-$5.21M-$28.3M-$29.9M-$32.1M
Diluted EPS-$0.57-$1.16-$0.95-$0.86
Net margin-47.0%-16645.3%-373362.5%-401812.5%

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$124M
EV / EBITDA—
EV / Sales15520.0
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-25.0%
FCF yield-20.5%

Quality & risk

ROIC (est.)-210.9%
Free cash flow-$26.4M
Total debt$900K
Net cash$4.43M
Altman Z-Score-15.75 distress
Piotroski F-Score2/7

Capital returns

Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+29.5%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Some governance/structural items recently, but no outright red flags.
  1. 8-K Shareholder vote2026-06-22
  2. 10-Q Quarterly report2026-05-07
  3. DEF 14A Proxy statement2026-04-29
  4. 8-K Material agreement2026-03-19
  5. 10-K Annual report2026-03-19
  6. 8-K Reg FD disclosure2026-02-02
  7. 8-K Other event2026-01-08
  8. 8-K Reg FD disclosure2026-01-05
  9. 8-K Officer / director change2026-01-02

Recent filings

all on EDGAR ↗
8-KPeriod ending 2026-06-162026-06-22open ↗4Period ending 2026-06-162026-06-18open ↗4Period ending 2026-06-162026-06-18open ↗4Period ending 2026-06-162026-06-18open ↗4Period ending 2026-06-162026-06-18open ↗4Period ending 2026-06-162026-06-18open ↗4Period ending 2026-06-162026-06-18open ↗4Period ending 2026-06-162026-06-18open ↗4Period ending 2026-06-162026-06-18open ↗4Period ending 2026-06-162026-06-18open ↗4Period ending 2026-06-032026-06-04open ↗4Period ending 2026-06-012026-06-02open ↗

Quality score

F
ValueGrowthProfitHealthMom.
ValueF
GrowthD
ProfitabilityF
Financial healthC+
Momentum—
  • ✗Revenue growing year-over-year
  • ✗Profitable (positive net income)
  • ✗Net margin above 10%
  • ✗Return on equity above 15%
  • ✓Liabilities below 2× equity
Revenue
$8.00K
+0.0% YoY
Net margin
-401812.5%
ROE
-278.5%
P/E
—

SEC fundamentals · FY 2025

'22'23'24'25

■ revenue · ■ net income, by fiscal year

Revenue$8.00K+0.0%
Net income-$32.1M-7.6%
Operating income-$33.2M-4.8%
Diluted EPS-$0.86+9.5%
Cash & equivalents$5.33M-37.7%
Total assets$19.0M-45.2%
Total liabilities$7.48M-11.4%
Stockholders' equity$11.5M-56.1%
Op.: -415175.0%L/E: 0.65x

Frequently asked

Is GENELUX Corp (GNLX) a buy?
GNLX currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.65x); but unprofitable (net margin -401812.5%).
What is GENELUX Corp's quality score?
GNLX scores 35.8235294117647/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001231457, latest 10-Q filed 2026-05-07) · EODHD · as of 6/26/2026, 7:35:14 PM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC
2026-06-16
Pulisic Matthew
Chief Financial Officer
Award279K
2026-06-16
Groen Eric
General Counsel
Award234K
2026-06-16
Cappello Joseph
Chief Technical Officer
Award175K
2026-06-16
Tyree James L
Director
Award28.4K
2026-06-16
Zindrick Thomas
President and CEO
Award731K
2026-06-16
Thomas John
Director
Award28.4K
2026-06-16
Mirabelli Mary
Director
Award28.4K
2026-06-16
Yu Yong
Chief Scientific Officer
Award119K

Earnings history

beat/miss · move
2025-03-25—▼ -12.60%8-K ↗
2024-02-02—▼ -7.28%8-K ↗

Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.

Recent news

market news →
Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesBullish
globenewswire.com· 2026-03-19
Weekly Buzz: ScinoPharm Gets FDA Nod; GNLX's Olvi-Vec Shows Promise; GLUE's MRT-8102 AdvancesBullish
nasdaq.com· 2026-01-09
Genelux Reports Positive Interim Results From Olvi-Vec Lung Cancer TrialsBearish
nasdaq.com· 2026-01-05
Genelux Corp Appoints Jason Litten CMOBullish
nasdaq.com· 2026-01-02
Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical OfficerBullish
globenewswire.com· 2026-01-02
Genelux Corporation to Participate in a Fireside Chat at Piper Sandler 37th Annual Healthcare ConferenceBearish
globenewswire.com· 2025-11-26

Vs tracked universe

compare →

1043 tracked peers · median

EDGAR Score36 vs 67
Revenue growth0.0% vs 7.1%
Net margin-401812.5% vs 10.5%
Return on equity-278.5% vs 12.3%
P/E— vs 25.5